Butyrate supplementation in CKD models has been found to alleviate kidney fibrosis and reduce inflammation by modulating pathways such as NLRP3-mediated pyroptosis and the STING/NF-κB/p65 pathway [81]. Here, NLRP3 is linked to chronic kidney disease.